Semaglutide (Ozempic / Wegovy) Drug Interactions
Semaglutide interaction management focuses on insulin/secretagogues, oral medications with monitoring requirements, levothyroxine considerations, contraceptive issues during vomiting/diarrhea, and dehydration-related co-medication risk. Injectable semaglutide has not shown a clinically significant reduction in oral contraceptive bioavailability, but oral semaglutide has shown a levothyroxine exposure effect.
Semaglutide interaction management focuses on insulin/secretagogues, oral medications with monitoring requirements, levothyroxine considerations, contraceptive issues during vomiting/diarrhea, and dehydration-related co-medication risk. Injectable semaglutide has not shown a clinically significant reduction in oral contraceptive bioavailability, but oral semaglutide has shown a levothyroxine exposure effect.
Key Takeaways
- Semaglutide can delay absorption of oral drugs, but most do not show clinically significant exposure changes.
- The most important interactions are insulin/sulfonylureas, narrow-therapeutic-index drugs, thyroid-medicine monitoring, and dehydration-risk medicines.
- It is not a major CYP interaction drug, gastric emptying is the main mechanism.
- Injectable semaglutide did not reduce oral contraceptive bioavailability in a study.
- Seek care for severe abdominal pain, persistent vomiting, hypoglycemia, allergic reaction, or vision changes.
Semaglutide Interactions at a Glance
| Property | Detail |
|---|---|
| Drug class | GLP-1 receptor agonist (Ozempic / Wegovy) |
| Main interaction mechanism | Delayed gastric emptying; additive pharmacodynamic effects |
| Highest-importance interactions | Insulin/sulfonylureas; narrow-therapeutic-index drugs; levothyroxine monitoring |
| Oral contraceptives | Injectable semaglutide did not reduce bioavailability in a study |
| CYP-mediated interactions? | Not a major feature |
How Semaglutide Interacts
Semaglutide delays gastric emptying, which can delay the time-to-peak concentration of some oral drugs. A systematic review found GLP-1 receptor agonists often reduce Cmax and delay Tmax but generally do not cause clinically significant changes in overall exposure for most medications. The clinically meaningful concerns are additive glucose-lowering with insulin/secretagogues, monitoring for narrow-therapeutic-index drugs, thyroid-dose changes after weight loss, and kidney risk from NSAIDs during dehydration.
On semaglutide with other medicines?
Check your full medication list for the interactions that actually matter. Allmeds scans it in minutes.
Top Clinically Significant Interactions
| Interaction Category | Mechanism | Significance | Patient-Facing Advice |
|---|---|---|---|
| Insulin / sulfonylureas | Additive glucose-lowering | High | Monitor glucose; clinician may reduce dose |
| Oral drugs needing monitoring | Delayed gastric emptying | Variable | Consider clinical/lab monitoring for narrow-therapeutic-index drugs |
| Levothyroxine | Absorption / weight-loss dose changes; oral-semaglutide T4 effect | Moderate | Monitor TSH if symptoms, major weight change, or oral-semaglutide use |
| Oral contraceptives | Injectable semaglutide did not reduce bioavailability in a study | Usually low | Backup if vomiting/diarrhea or missed pills |
| NSAIDs / dehydration | Kidney risk if volume-depleted | Moderate in susceptible patients | Avoid NSAIDs during GI illness unless advised |
Common Questions About Semaglutide Interactions
It can delay absorption, but most drugs do not show clinically significant exposure changes.
Insulin/sulfonylureas, narrow-therapeutic-index drugs, thyroid-medicine monitoring, and dehydration-risk medicines.
No clinically significant CYP/transporter interaction is a major feature; gastric emptying is the main mechanism.
Injectable semaglutide did not reduce oral contraceptive bioavailability in a study.
Severe abdominal pain, persistent vomiting, hypoglycemia, allergic reaction, or vision changes should be assessed.
Check semaglutide against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic / Wegovy / Mounjaro EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.